EVAX
Evaxion Biotech A/SNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.40
P/S
3.12
EV/EBITDA
-0.90
DCF Value
$40.68
FCF Yield
-28.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-122.7%
Net Margin
-102.4%
ROE
-61.6%
ROA
-27.2%
ROIC
-33.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $22.0K | $-5.9M | $-0.89 |
| FY 2025 | $7.6M | $-7.7M | $-1.21 |
| Q3 2025 | $7.5M | $4.6M | $4.20 |
| Q2 2025 | $37.0K | $-4.8M | $-4.40 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$10.50
Target (Median)
$10.50
Target Range
$10.00 - $11.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
DK
Exchange
NASDAQ
Beta
0.20
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.